FIELD: chemistry.
SUBSTANCE: invention relates to use of a sigma ligand, which is a 4-{2-[5-methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yloxy]ethyl}morpholine or a pharmaceutically acceptable salt thereof.
EFFECT: prevention and/or treatment of pain associated with type 2 diabetes and related symptoms.
6 cl, 9 dwg, 4 ex
Title | Year | Author | Number |
---|---|---|---|
SIGMA-LIGANDS FOR APPLICATION IN PREVENTION AND/OR TREATMENT OF POSTOPERATIVE PAIN | 2011 |
|
RU2569055C2 |
SIGMA-RECEPTOR LIGANDS FOR PREVENTING OR TREATING PAIN CAUSED BY CHEMOTHERAPY | 2010 |
|
RU2543382C2 |
SIGMA LIGANDS FOR POTENTIATING ANALGESIC EFFECT OF OPIOIDS AND OPIATES IN POSTOPERATIVE PAIN AND ATTENUATING DEPENDENCY THEREOF | 2011 |
|
RU2563460C2 |
USE OF SIGMA LIGANDS WITH INDUCED OPIOIDS HYPERALGESIA | 2011 |
|
RU2589899C2 |
SIGMA-RECEPTOR INHIBITORS | 2005 |
|
RU2417987C2 |
USE OF SIGMA LIGANDS FROM PAIN IN BONE CANCER | 2011 |
|
RU2585095C2 |
PHARMACEUTICAL COMPOSITIONS CONTAINING SIGMA RECEPTOR LIGANDS | 2010 |
|
RU2549882C2 |
USING COMPOUNDS BINDING TO SIGMA RECEPTOR LIGANDS FOR TREATING NEUROPATHIC PAIN PROGRESSION CAUSED BY CHEMOTHERAPY | 2009 |
|
RU2537226C2 |
1-ARYL-3-AMINOALKOXYPYRAZOL AS SIGMA LIGANDS INTENSIFYING ANALGESIC ACTION OF OPIOIDS AND RELIEVING ADDICTION THERETO | 2009 |
|
RU2519060C2 |
NEW PREVENTIVE AND/OR THERAPEUTIC AGENT FOR NEUROPATHIC PAIN | 2008 |
|
RU2462459C2 |
Authors
Dates
2017-01-26—Published
2012-05-18—Filed